3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Gastro-enteropancreatic neuroendocrine tumor
2
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Central Nervous System Neoplasms
1
Interventions
Temozolomide
3
Irinotecan
3
tozuleristide
2
selpercatinib
2
lenvatinib
2
gadobenic acid
2
avelumab
2
Radiation
2
Paclitaxel
2
Leflunomide
2
Immunotherapy
2
Gemcitabine
2
Everolimus
2
Cisplatin
2
Carboplatin
2
Cancer Vaccines
2
Bevacizumab
2
Adjuvants, Immunologic
2
ridaforolimus
1
regorafenib
1
prinomastat
1
pomalidomide
1
perillyl alcohol
1
pemigatinib
1
pembrolizumab
1
pamiparib
1
omburtamab I-131
1
irinotecan sucrosofate
1
interferon gamma-1b
1
infigratinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Central Nervous System Neoplasms
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled